Effects of JL13, a Pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 1, 2001, Pages 386-391

  Ellenbroek, Bart A ^a,e   Liégeois, Jean François ^b,d   Bruhwyler, Jacques ^c   Cools, Alexander R ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Therabel Pharma Belgium   (Belgium)

^d FNRS   (Belgium)

^e Department of Psychoneuropharmacology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 METHYLPIPERAZIN 1 YL) 8 CHLOROPYRIDO[2,3 B][1,5]BENZOXAZEPINE FUMARATE; AMPHETAMINE; APOMORPHINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PYRIDOBENZOXAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG OXIDATION; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; REACTION TIME; SCHIZOPHRENIA; STARTLE REFLEX; TREATMENT OUTCOME;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINONES; CENTRAL NERVOUS SYSTEM STIMULANTS; CLOZAPINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HALOPERIDOL; LOCOMOTION; MALE; PYRIDINES; RATS; RATS, WISTAR; SCHIZOPHRENIA; STARTLE REACTION;

EID: 0034978205     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Pharmacological differentiation of classical and novel antipsychotics
2. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
3. Prestimulus effects of human startle reflex in normals and schizophrenics
4. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties
5. Comparative study of typical neuroleptics, clozapine and newly synthesized clozapine·analogues: Correlations between neurochemistry and behaviour
6. New dibenzazepine derivatives with disinhibitery and/or antidepressant potential: Neurochemical and behavioural study in the open-field and forced swimming tests
7. 13, a putative antipsychotic, in Cebus non-human primates
8. Search after neurobiological profile of individual-specific features of Wistar rats
9. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: Effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine
10. Animal models of schizophrenia
11. Potentiation of prepulse inhibition of the startle reflex in rats: Pharmacological evaluation of the procedure as a model for detecting antipsychotic activity
12. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs
13. The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine
14. The paw test: An animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism
15. Animal models for schizophrenia: An introduction
16. Activity of "seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine
17. The paw test: A behavioral paradigm for differentiating between classical and atypical neuroleptic drugs
18. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats
19. Simulation models for schizophrenia
20. The effects of an early stressful life event on sensorimotor gating in adult rats
21. Animal models of psychiatric disorders
22. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia
23. Comparative characterisation in the discriminative stimulus properties of clozapine and other antipsychotics in rats
24. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatal and the nucleus accumbens
25. Rat strain differences in the ability to disrupt sensorimotor gating are limited to the dopaminergic system, specific to prepulse inhibition, and unrelated to changes in startle amplitude or nucleus accumbens dopamine receptor sensitivity
26. Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: Application to antipsychotic drugs
27. JL 13, a potential successor to clozapine is less sensitive to oxidative phenomenons
28. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study
29. Hypochlorous acid, a major oxidant produced by activated neutrophils, has low effect on two pyridobenzoazepine derivatives. JL 3 and JL 13
30. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat
31. Dopaminergic stimulation disrupts se n sorimotor gating in the rat
32. Serotonin 5HT2 antagonists: A preclinical evaluation of possible therapeutic effects
33. Interactions between neuroleptics and 5-HT1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects
34. Effects of haloperidol and SCH 23390 on acoustic startle and prepulse inhibition under basal and stimulated conditions
35. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats
36. 8-OH-DPAT disruption of prepulse inhibition in rats: Reversal with (+)WAY 100,135 and localization of site of action
37. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
38. Discrepant findings of clozapine effects on prepulse inhibition of startle: Is it the route or the rat?